Primers used in reverse transcription and quantitative real-time PCR.

<p>Primers used in reverse transcription and quantitative real-time PCR.</p

Figure 2

<p><b>Transfection efficiency and </b><b><i>in vivo</i></b><b> bioluminescence imaging.</b> (A) Expression of miR-26a after transfection with different concentrations of Ad5-anti-miR-26a-LUC, Ad5-LUC, or no transfection (control). (B) Expression of miR-26a after transfection with different concentrations of Ad5-miR-26a-LUC, Ad5-LUC, or no transfection (control). The degree of bioluminescence was the greatest in Ad5-anti-miR-26a-LUC (AA) group (C), less in Ad5-LUC (AL) group (E), and the weakest in Ad5-miR-26a-LUC (AM) group (D). The mice in control group showed no bioluminescence image (F). ^*<i>P</i><0.05, ^**<i>P</i><0.01, ^***<i>P</i><0.001.</p

Figure 4

<p><b>CCND2 and CCNE2 are potential targeted genes of miR-26a.</b> (A) Anti-miR-26a expression increased the mRNA expression of CCND2 and CCNE2 as shown by qRT-PCR. Conversely, miR-26a over-expression declined the mRNA expression of the two genes. The mRNA expression of CCNE1 and CDK6 showed no obvious change. (B) Anti-miR-26a expression up-regulated the protein expression of CCND2 and CCNE2. In contrast, miR-26a over-expression down-regulated the protein expression of CCND2 and CCNE2. The protein expression of CCNE1 and CDK6 showed no obvious change. (C and D) Expression of CCND1 and CCND3 in both mRNA and protein level showed no obvious changes. ^*<i>P</i><0.05, ^**<i>P</i><0.01, ^***<i>P</i><0.001.</p

Figure 3

<p><b>Anti-miR-26a expression promotes liver regeneration and improves liver function in mice.</b> (A) LBWR of mice transfected with Ad5-anti-miR-26a-LUC (AA), Ad5-miR-26a-LUC (AM) and Ad5-LUC (AL). There was an increased LBWR in AA group compared to AL group (<i>P</i><0.001), and a decreased LBWR in AM group can be seen compared with AL group at 120 h (<i>P</i><0.001). (B) The Ki-67 proliferation index (PI) after 70% PH and transfection, was significantly higher in AA group compared with AL group (<i>P</i><0.001), while lower in AM group in comparison with AL group (<i>P</i><0.001). (C-E) Liver function tests after transfection, worse liver functions could be observed in AM group compared with AL group. ^*<i>P</i><0.05, ^**<i>P</i><0.01, ^***<i>P</i><0.001.</p

Univariate analysis of potential variables influencing the test performance of perforin during AR.

a<p>Three independent data points are required at least to draw an SROC curve.</p><p>Abbreviations: DOR, diagnostic odds ratio; CI, confidence interval; AUC, area under the curve of the SROC curve; PBL, peripheral blood leukocyte; PCR, polymerase chain reaction; RT-PCR, reverse transcription polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.</p

Study characteristics of each included study.

<p>Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN, true negative; PBL, peripheral blood leukocyte; RT-PCR, reverse transcription polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.</p

Flow chart describing the literature search conducted for this meta-analysis.

<p>Flow chart describing the literature search conducted for this meta-analysis.</p

Table_1_Association between nonalcoholic fatty liver disease and increased glucose-to-albumin ratio in adults without diabetes.docx

BackgroundNonalcoholic fatty liver disease (NAFLD) affects approximately 30% of individuals globally. Both serum glucose and albumin were demonstrated to be potential markers for the development of NAFLD. We hypothesized that the risk of NAFLD may be proportional to the glucose-to-albumin ratio (GAR).MethodsBased on information from the National Health and Nutrition Examination Survey (NHANES) 1999–2018, it was determined that GAR was associated with an increased risk of NAFLD and liver fibrosis utilizing weighted multivariable logistic regression. Participants with a fatty liver index (FLI) over 60 were identified with NAFLD, and those with an NAFLD fibrosis score (NFS) >0.676 with evidence of NAFLD were labeled with advanced hepatic fibrosis (AHF). The liver biopsy was utilized to verify the relationship between GAR and FLD in our center cohort. Mendelian randomization analysis investigated the genetic relationship between GAR and NAFLD.ResultsOf 15,534 eligible participants, 36.4% of participants were identified as NAFLD without AHF. GAR was positively correlated with the probability of NAFLD following full adjustment for possible variables (OR = 1.53, 95% CI: 1.39–1.67). It was confirmed that patients with NAFLD and AHF had an inferior prognosis. The relationship between GAR and NFS was favorable (R = 0.46, PConclusionAmong participants without diabetes, greater GAR was linked to higher risks of NAFLD. In addition, NAFLD patients with higher GAR tended to develop liver fibrosis and adverse outcomes.</p

Overall DOR and SROC curves for all data sets describing the diagnostic performance of perforin mRNA detection in identifying AR.

<p>(A) Overall DOR. (B) The SROC curves for all data sets. Effect sizes were pooled by random-effects models. The pooled DOR is shown as a solid diamond. Each square in the SROC curve represents one study. Sample size is indicated by the size of the square.</p

Search algorithm and study selection outcomes.

<p>Search algorithm and study selection outcomes.</p